Huntsman Cancer Institute Receives NIH Grant for Clinical Trial of Curacyte's PHP
16-Sep-2005
Curacyte's PHP is a scavenger of nitric oxide (NO), the main causative agent responsible for vasodilation and hypotension in distributive shock. PHP has been demonstrated to reverse the vasodilation and resolve the hypotension associated with distributive shock. PHP has completed Phase II clinical studies in distributive shock and is entering a Phase III study. Additional clinical studies of PHP in patients with cardiogenic shock are also planned.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.